参考文献/References:
[1] Jadvar H. Molecular imaging of prostate cancer a concise synopsis. Mol Imaging, 2009. 8(2):56-64.
[2] 中华眹学会泌尿外科分会.前列腺癌诊断治疗指南.中华现代外科学杂志,2006,3(22>:1839-1856.
[3] Anastasi A, Erspamer V, Bucci M. Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia, 1971, 27(2):166-167.
[4] Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol, 2007, 18(9):1457-1466.
[5] Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate:relation to neoplastic transformation. Cancer Res, 1999,59(5):1152-1159.
[6] Stangelberger A, Schally AV, Djavan B. New treatment approaches for prostate cancer based on peptide analogues. Eur Urol, 2008, 53(5):890-900.
[7] Schroeder RP, van Weerden WM, Bangma Cf et al. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods 2009,48(2):200-204.
[8] Yang YS, Zhang X, Xiong Z, et al. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol, 2006, 33(3):371-380.
[9] Duncan JR, Stephenson MT, Wu HP, et al. Indium-111-diethylene-triaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res, 1997,57(4):659-671.
[10] Maecke HR, Hofmann M, Haberkom U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med, 2005,46(Suppl 1):172S-178S.
[11] Maina T, Nock B, Mather S. Targeting prostate cancer with radiolabelled bombesins. Cancer Imaging, 2006,6:153-157.
[12] Zhang X, Cai W, Cao F, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing proslate cancer. J Nucl Med, 2006,47(3):492-501,
[13] Chen X, Park R, Hou Y, et al. Micro PET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3] bombesin in human prostate adenocarcinoma xenografts. J Nucl Med, 2004,45(8):1390-1397.
[14] Lantry LE, Cappeiletti E, Maddalena ME, et al. 177Lu-AMBA:synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med, 2006, 41(1):1144-1152.
[15] Johnson CV. Shelton T, Smith CJ, et al. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH (2) GRP receplor-largeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biolher Radiophamu 2006, 21(2):155-166.
相似文献/References:
[1]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[2]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[3]刘辰,杨悦,张雪宁,等.MRI和1997年版Partin表对前列腺癌病理特征预测准确性的对比研究[J].国际放射医学核医学杂志,2015,39(2):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
Liu Chen,Yang Yue,Zhang Xuening,et al.Accuracy of MRI and 1997 edition of Partin tables in predicting the pathological features of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
[4]桂继琮,刘兴党.镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展[J].国际放射医学核医学杂志,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
Gui Jicong,Liu Xingdang.Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
[5]张晖,段清,卓娜,等.经直肠超声引导下“6+X”点法前列腺穿刺活检诊断前列腺癌的临床价值分析[J].国际放射医学核医学杂志,2015,39(4):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
Zhang Hui,Duan Qing,Zhuo Na,et al.Meta-analysis of the diagnostic value of transrectal ultrasound-guided “6+X” points biopsy in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
[6]张龙敏,刘爱连.前列腺癌MRI诊断技术研究进展[J].国际放射医学核医学杂志,2014,38(1):53.[doi:10.3760/cma.j.issn 1673-4114.2014.01.011]
Zhang Longmin,Liu Ailian.Advances in MRI diagnosis of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):53.[doi:10.3760/cma.j.issn 1673-4114.2014.01.011]
[7]刘辰,杨悦,张雪宁,等.CT/MRI图像融合在前列腺癌IMRT中的应用进展[J].国际放射医学核医学杂志,2014,38(4):247.[doi:10.3760/cma.j.issn.1673-4114.2014.04.010]
Liu Chen,Yang Yue,Zhang Xuening,et al.CT/MRI image fusion in intensity modulated radiation therapy for prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):247.[doi:10.3760/cma.j.issn.1673-4114.2014.04.010]
[8]袁超,李卫鹏,胡永全,等.89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察[J].国际放射医学核医学杂志,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
YUAN Chao,LI Wei-peng,HU Yong-quan,et al.Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
[9]韦赐秋.中老年男性血清前列腺特异性抗原测定的临床价值[J].国际放射医学核医学杂志,2010,34(5):302.[doi:10.3760/cma.j.issn.1673-4114.2010.05.014]
[10]徐慧琴,薛杨央,赵学峰,等.18F-FDG PET-CT诊断前列腺癌复发与转移的价值[J].国际放射医学核医学杂志,2011,35(2):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]
XU Hui-qin,XUE Yang-yang,ZHAO Xue-feng,et al.Value of 18F-FDG PET-CT in diagnoss of prostate cancer recurrence and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]